Healthtech investors prioritise start-ups that address validated clinical or operational pain points with quantifiable market demand. Key investment criteria include a scalable business model with a realistic go-to-market strategy, adaptable leadership capable of handling regulatory and reimbursement pathways (especially across fragmented markets like the GCC), and proof of traction through pilot outcomes or user retention rather than technology alone.
The race to transform healthcare is attracting billions in investment, with start-ups developing new approaches to everything from diagnostics and clinical decision-making to connected care and healthcare operations.
In the US, for instance, digital health start-ups secured US$14.2 billion in 2025, up 35% from the previous year, according to a Rock Health report. Closer to home, healthtech start-ups across the GCC attracted US$148 million in disclosed investment between January 2025 and July 2026, according to PitchBook data. Across five GCC markets, 32 companies secured funding, led by Saudi Arabia with 17 and the UAE with 11.
Yet more capital does not necessarily mean an easier path to investment. According to Rock Health’s latest data, the number of US digital health deals fell 5% from 509 in 2024 to 482 in 2025, while mega deals of US$100 million or more accounted for 42% of total funding, their highest share since 2021.
For founders, the message is clear: there is capital available, but investors are making increasingly selective bets. So what are they looking for?
1. A real problem worth solving
An impressive technology may capture attention, but investors look for something simpler: what problem does it solve?
For Dr Louiza Chitour, Co-Founder of 10FT Ventures, one of the most common mistakes founders make is letting the product dominate the pitch before establishing why it needs to exist. “The most common mistake is leading with the product instead of the problem,” she said in an interview with WHX Insights. “I don’t need to see your app before I understand, specifically and with numbers, the pain it removes.”
According to the Rock Health report, artificial intelligence-enabled companies captured 54% of US digital health funding in 2025. But as AI becomes increasingly embedded across healthcare innovation, using the technology is not, by itself, a differentiator.
2. A market you can actually reach
A multibillion-dollar market figure can make an impressive slide, but investors want to understand the opportunity a start-up can realistically capture. Chitour cautions against citing the value of the entire GCC healthcare sector without explaining how that translates into the company’s first 100 customers. Instead, founders should know who will buy their solution, what they are willing to pay and how the business intends to reach them.
This is where market potential meets scalability: can early success be replicated across more customers and markets without costs growing at the same pace?
3. A team that can adapt
At an early stage, investors may have limited revenue, customer or performance data to evaluate. That makes the founding team itself a critical part of the investment case. For Chitour, team and “market-truth” carry the greatest weight early on, followed by scalability, with traction acting as a tiebreaker. Importantly, she sees these factors as connected rather than individual boxes to tick.
How a founder discusses a previous mistake can also reveal whether they can adapt when the evidence demands it. “I also closely watch how a founder responds to a hard question in the room in real time,” Chitour said. “Curiosity versus defensiveness is a better predictor of adaptability than anything in their deck.”
Strong healthtech teams may also combine skills that rarely exist in one person: clinical or scientific credibility and commercial execution.
4. A credible route to market
A healthtech solution does not move from idea to large-scale adoption on technology alone. Founders must understand the healthcare systems they intend to operate in.
“In health specifically, I have one absolute non-negotiable: does the founder actually understand the regulatory and reimbursement pathway for the specific market they’re starting in – not generically, but country by country,” said Chitour.
This is especially relevant for start-ups looking to scale across the GCC, where regulatory and reimbursement requirements cannot be assumed to be interchangeable from one market to another.
Chitour has seen promising products stall for months because founders underestimated those differences or discovered too late that they needed additional regulatory approval.
Investors therefore want to see that regulation, reimbursement, payer dynamics and procurement have been considered from the outset. Knowing who will use a product matters; knowing who approves, buys and ultimately pays for it can be just as critical.
5. Evidence that backs up the ambition
Investors expect founders to think big, although ambition becomes more persuasive when backed by evidence.
For an early-stage start-up, that does not necessarily mean millions in revenue. Pilot outcomes, repeat usage, customer retention, willingness to pay and early contracts can all demonstrate meaningful traction.
Chitour describes “precision, not polish” as the quality that makes a pitch memorable. She recommends starting with a real patient, clinician, provider, or customer who illustrates the problem before moving to the start-up’s advantage, proof points, and business model.
The final ask should be equally specific. Founders need to explain how much they are raising, where the money will go and what milestones that capital should enable over the following 12 to 18 months.
For healthtech founders, the opportunity is significant, but so is the competition for capital. A compelling technology may get an investor’s attention; proving it can become a viable, scalable business is what can turn interest into investment.
For founders preparing the pitch of their lifetime, Chitour offers one final piece of advice: “Lead with the risk you’ve already solved, not the vision you still have to prove.”
Frequently Asked Questions about Healthtech Investment
What do investors look for in a healthtech innovator before investing?
Investors evaluating what healthtech investors look for prioritise healthtech innovators who solve a validated clinical or operational pain point supported by data. Rather than relying solely on advanced technology or artificial intelligence, investors focus on startup adaptability, clear regulatory and reimbursement pathways, and proven unit economics.
How can founders deliver a high-impact healthtech startup pitch?
A successful healthtech startup pitch follows a “precision, not polish” framework. Founders should lead with a specific problem experienced by a real clinician or patient, outline the regulatory risks already solved, explain their go-to-market execution strategy, and define a precise funding request tied to 12-to-18-month operational milestones.
What are the primary drivers of GCC healthtech investment?
GCC healthtech investment is driven by rapid digital transformation and expanding healthcare infrastructure in key markets such as Saudi Arabia and the United Arab Emirates. To secure capital, startups must demonstrate localised market penetration strategies and account for country-specific regulatory approvals across the region.
How does global digital health funding affect early-stage startups?
Current global digital health funding trends show that while overall capital deployment remains strong, investors are making more selective bets concentrated in larger deals. For early-stage companies seeking a healthtech investment, success requires proving commercial viability through pilot outcomes, repeat customer usage, and strategic contracts rather than top-line projections.
What determines if a healthtech startups investment is ready for international scaling?
A healthtech startups investment is ready for global scaling when the company demonstrates that its solution can be replicated across international markets without costs scaling at the same pace. This requires a founding team that combines deep clinical credibility with commercial execution and cross-border regulatory expertise.
